Scholarlink

Introduction <p>To evaluate the efficacy of tranexamic acid (TXA) in blepharoplasty surgery.</p> Methods <p>A meta-analysis was conducted following PRISMA guidelines. PubMed, Web of Science, Cochrane Library, and Scopus databases were searched for randomized controlled trials (RCTs). Data extraction focused on outcomes, such as ecchymosis scores, time to recovery, intraoperative pain, operative time, and hemostasis quality. The risk of bias was assessed using the ROB 2 tool. RevMan 5.4 software was used for meta-analysis with mean differences (MD) and standardized MD (SMD) calculated for various outcomes.</p> Results <p>Five RCTs comprising 594 participants (1154 eyes) met the inclusion criteria. Overall, TXA significantly reduced postoperative ecchymosis on postoperative days (POD) 1 and 7 (SMD = –&#xa0;0.54, 95% CI: [–&#xa0;0.71 to –&#xa0;0.38], <i>p</i> &lt; 0.00001) with moderate heterogeneity (<i>I</i><sup>2</sup> = 50%). TXA significantly shortened patient-reported recovery time (MD = –&#xa0;0.72 days, 95% CI: [–&#xa0;1.02 to –&#xa0;0.42], <i>p</i> &lt; 0.00001) with homogeneity (<i>I</i><sup>2</sup> = 0%). Also, TXA significantly reduced operative time (MD = –&#xa0;1.20 minutes, 95% CI: [–&#xa0;2.39 to –&#xa0;0.01], <i>p</i> &lt; 0.05). On the other hand there was no significant difference in intraoperative pain scores or surgeon-assessed hemostasis quality for SC TXA; however, IV TXA improved hemostasis assessment (MD = –&#xa0;0.70, 95% CI: [–&#xa0;1.02 to –&#xa0;0.38], <i>p</i> &lt; 0.0001).</p> Conclusion <p>TXA significantly reduces ecchymosis, expedites recovery, and enhances operative time and hemostasis in blepharoplasty. These findings support TXA’s use as an effective adjunct to improve blepharoplasty recovery, although further studies are warranted to optimize dosing and minimize thromboembolic risks.</p> Level of Evidence I <p>This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors <a href="http://www.springer.com/00266">www.springer.com/00266</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating Tranexamic Acid's Role in Upper Eyelid Blepharoplasty: A Systematic Review and Meta-Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月28日

查看全文
  • Mohamed Abo Zeid,
  • Kareem Khalefa,
  • Mohammad Al Diab Al Azzawi,
  • Amr Elrosasy,
  • Amr M. Abou Elezz,
  • Mohamed S. I. Mohamed,
  • Richard C. Allen,
  • Hashem Abu Serhan

摘要

Introduction

To evaluate the efficacy of tranexamic acid (TXA) in blepharoplasty surgery.

Methods

A meta-analysis was conducted following PRISMA guidelines. PubMed, Web of Science, Cochrane Library, and Scopus databases were searched for randomized controlled trials (RCTs). Data extraction focused on outcomes, such as ecchymosis scores, time to recovery, intraoperative pain, operative time, and hemostasis quality. The risk of bias was assessed using the ROB 2 tool. RevMan 5.4 software was used for meta-analysis with mean differences (MD) and standardized MD (SMD) calculated for various outcomes.

Results

Five RCTs comprising 594 participants (1154 eyes) met the inclusion criteria. Overall, TXA significantly reduced postoperative ecchymosis on postoperative days (POD) 1 and 7 (SMD = – 0.54, 95% CI: [– 0.71 to – 0.38], p < 0.00001) with moderate heterogeneity (I2 = 50%). TXA significantly shortened patient-reported recovery time (MD = – 0.72 days, 95% CI: [– 1.02 to – 0.42], p < 0.00001) with homogeneity (I2 = 0%). Also, TXA significantly reduced operative time (MD = – 1.20 minutes, 95% CI: [– 2.39 to – 0.01], p < 0.05). On the other hand there was no significant difference in intraoperative pain scores or surgeon-assessed hemostasis quality for SC TXA; however, IV TXA improved hemostasis assessment (MD = – 0.70, 95% CI: [– 1.02 to – 0.38], p < 0.0001).

Conclusion

TXA significantly reduces ecchymosis, expedites recovery, and enhances operative time and hemostasis in blepharoplasty. These findings support TXA’s use as an effective adjunct to improve blepharoplasty recovery, although further studies are warranted to optimize dosing and minimize thromboembolic risks.

Level of Evidence I

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266.